All In Biotech

Drug Trial Radar · NCT04492488

A Study of MRG002 in Patients with HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer

An Open-Label, Multi-center Phase I/II Dose Escalation and Expansion Study to Assess the Safety, Efficacy and Pharmacokinetics of MRG002 in Patients with HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer

Last checked: Nov 19, 2026Latest source record: Oct 22, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

129

Planned (sponsor's estimate)

Start

May 24, 2021

Primary completion

Oct 18, 2022

Study completion Dec 31, 2024

Sponsor

Lead sponsor
Shanghai Miracogen Inc.Industry
Sponsor type
Industry
First posted
Jul 30, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this study is to assess the safety, efficacy, and pharmacokinetics of MRG002, as well as the immunogenicity as defined by the incidence of anti-drug antibody (ADA) of MRG002 in patients with HER2-positive advanced solid tumors and locally advanced or metastatic gastric/gastroesophageal junction (GEJ) cancer.

Conditions

  • Advanced Solid Tumors
  • Advanced or Metastatic Gastric Cancer
  • Advanced or Metastatic Gastroesophageal Junction Cancer

Interventions

  • MRG002Drug

    Administrated intravenously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Tolerated Dose (MTD)Time frame: DLT will be evaluated during the first 21-day treatment cycle (Cycle 1)
  2. Recommended Phase II Dose (RP2D)Time frame: Day 1 to Day 21 of Cycle 1
  3. Objective Response Rate (ORR)Time frame: Baseline to study completion (24 months)
  4. Incidence of Adverse Events (AEs)Time frame: After signing informed consent until 45 days after the last dose of MRG002

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • University of California Irvine Chao Family Comprehensive Cancer Center

    Orange, California

  • MD Anderson Cancer Center

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.